Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | CCR6 | P51684 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiourea SCHEMBL9809709 | 0.85 | GSK3A (0.65) | GSK3AGSK3BCCR6 | |
| Urea SCHEMBL8556796 | 0.76 | GSK3A (0.69) | GSK3AGSK3BCCR6ALDH1A1 | |
| Hydroxyamine SCHEMBL27087760 | 0.76 | — | — | |
| Carbamic Acid SCHEMBL6022388 | 0.74 | GSK3A (0.65) | GSK3AGSK3BCCR6HSD17B10 | |
| Maleic Hydrazide SCHEMBL10455079 | 0.73 | GSK3A (0.48) | GSK3AGSK3BCCR6ALDH1A1 | |
| SCHEMBL9989664 | 0.73 | — | — | |
| Hydrazine SCHEMBL3175189 | 0.73 | — | — | |
| SCHEMBL28058947 | 0.73 | — | — | |
| SCHEMBL33524954 | 0.72 | — | — | |
| SCHEMBL1599522 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239790-A1 | NOVEL RECOMBINANT PROTEINS WITH N-TERMINAL FREE THIOL | POOL CHADLER | 2009-09-24 | — | — | US | disclosed |
| EP-1699920-A4 | NOVEL RECOMBINANT PROTEINS WITH N-TERMINAL FREE THIOL | CENTOCOR INC (US) | 2008-05-28 | — | — | EP | disclosed |
| CN-1902311-A | Novel recombinant proteins with n-terminal free thiol | CENTOCOR INC (US) | 2007-01-24 | — | — | CN | disclosed |
| EP-1699920-A2 | NOVEL RECOMBINANT PROTEINS WITH N-TERMINAL FREE THIOL | CENTOCOR, INC. (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7074755-B2 | Erythropoietin conjugate compounds with extended half-lives | CENTOCOR, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20060116322-A1 | Formation of novel erythropoietin conjugates using transglutaminase | CENTOCOR, INC. | 2006-06-01 | — | — | US | disclosed |
| US-6995245-B2 | Formation of novel erythropoietin conjugates using transglutaminase | CENTOCOR, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050170457-A1 | Novel recombinant proteins with N-terminal free thiol | CENTOCOR, INC. | 2005-08-04 | — | — | US | disclosed |
| WO-2005065239-A2 | NOVEL RECOMBINANT PROTEINS WITH N-TERMINAL FREE THIOL | CENTOCOR, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20040266690-A1 | Formation of novel erythropoietin conjugates using transglutaminase | CENTOCOR INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004106373-A1 | ERYTHROPOIETIN CONJUGATE COMPOUNDS WITH EXTENDED HALF-LIVES | CENTOCOR, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040229318-A1 | Erythropoietin conjugate compounds with extended half-lives | CENTOCOR, INC. | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266690-A1 | Formation of novel erythropoietin conjugates using transglutaminase | EPOR, HBG2, TGM3 | GSK3A 2658/4885GSK3B 2945/4885CCR6 3036/4885 |
| US-20060116322-A1 | Formation of novel erythropoietin conjugates using transglutaminase | EPOR, HBG2, TGM3 | GSK3A 2658/4885GSK3B 2945/4885CCR6 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.